Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Intangibles (2016 - 2025)

Insight Molecular Diagnostics' Intangibles history spans 6 years, with the latest figure at $440000.0 for Q4 2025.

  • On a quarterly basis, Intangibles changed 0.0% to $440000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $440000.0, a 0.0% change, with the full-year FY2025 number at $440000.0, changed 0.0% from a year prior.
  • Intangibles hit $440000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $15.0 million in the prior quarter.
  • Over the last five years, Intangibles for IMDX hit a ceiling of $95.2 million in Q2 2021 and a floor of $440000.0 in Q2 2024.
  • Historically, Intangibles has averaged $51.4 million across 5 years, with a median of $56.8 million in 2023.
  • Biggest five-year swings in Intangibles: tumbled 99.23% in 2024 and later skyrocketed 3318.18% in 2025.
  • Tracing IMDX's Intangibles over 5 years: stood at $61.7 million in 2021, then rose by 0.27% to $61.9 million in 2022, then dropped by 8.0% to $56.9 million in 2023, then tumbled by 99.23% to $440000.0 in 2024, then changed by 0.0% to $440000.0 in 2025.
  • Business Quant data shows Intangibles for IMDX at $440000.0 in Q4 2025, $15.0 million in Q3 2025, and $15.0 million in Q2 2025.